Corman M L, Galandiuk S, Block G E, Prager E D, Weiner G J, Kahn D, Abdel-Nabi H, Mitchell E P, Pascucci V L, Maroli A N
Sansum Medical Clinic, Santa Barbara, California 93102-1239.
Dis Colon Rectum. 1994 Feb;37(2):129-37. doi: 10.1007/BF02047534.
The role of immunoscintigraphy with 111In-satumomab pendetide in the medical and/or surgical management of colorectal cancer patients was evaluated in a multicenter trial.
This 103 patient study population included 46 individuals with rising serum carcinoembryonic antigen levels and otherwise negative diagnostic evaluation, 29 patients with known recurrence, presumed to be isolated and resectable, and 28 patients for whom standard diagnostic tests provided equivocal information.
No adverse reactions were noted following intravenous administration of 1 mg of satumomab pendetide radiolabeled with approximately 5 mCi of 111In. Thirty percent of patients developed human anti-mouse antibodies postinfusion. In the 84 patients for whom correlation with histopathologic, diagnostic, and/or clinical findings was available, antibody imaging demonstrated a sensitivity of 73 percent in patients with confirmed tumor (36/49) and negative results for all 35 patients with no evidence of malignancy. Occult disease was detected in 18 patients.
111In-satumomab pendetide immunoscintigraphy was helpful in the medical and/or surgical management of 45 (44 percent) patients and provided information unavailable from other diagnostic modalities.
在一项多中心试验中评估了用111铟-奥曲肽进行免疫闪烁显像在结直肠癌患者医学和/或外科治疗中的作用。
这项纳入103例患者的研究人群包括46例血清癌胚抗原水平升高而其他诊断评估为阴性的个体、29例已知复发且推测为孤立性且可切除的患者以及28例标准诊断检查提供了模棱两可信息的患者。
静脉注射1毫克用约5毫居里的111铟标记的奥曲肽后未观察到不良反应。30%的患者在输注后产生了人抗鼠抗体。在84例可将抗体显像结果与组织病理学、诊断和/或临床发现进行对比的患者中，抗体显像在确诊肿瘤的患者（36/49）中显示出73%的敏感性，而在所有35例无恶性肿瘤证据的患者中结果均为阴性。在18例患者中检测到隐匿性疾病。
111铟-奥曲肽免疫闪烁显像对45例（44%）患者的医学和/或外科治疗有帮助，并提供了其他诊断方法无法获得的信息。
